( NASDAQ-SMALL:BLRX,TelAviv:BLRX )

News from BioLineRx A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jan 04, 2017, 07:00 ET BioLineRx to Present at Biotech Showcase 2017 Conference in San Francisco

BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising...


Mar 10, 2016, 06:00 ET BioLineRx to Present at 2016 Annual Roth Conference in Southern California on March 14

BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising...


Feb 12, 2014, 07:00 ET BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia

BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising...


Jan 21, 2014, 07:00 ET BioLineRx Receives Approval to Commence Pivotal Trial for Novel Skin Lesion Treatment

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...


Jan 13, 2014, 07:00 ET BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization Treatment

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...


Jan 08, 2014, 07:00 ET BioLineRx and JHL Biotech to Collaborate on Type 1 Diabetes Antibody Treatment

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...


Jan 07, 2014, 08:00 ET BioLineRx to Present at Biotech Showcase Conference in San Francisco

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...


Dec 18, 2013, 07:00 ET BioLineRx Enters Clinic with Novel Treatment for Celiac Disease

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...


Dec 16, 2013, 07:00 ET BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...


Dec 10, 2013, 07:00 ET BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference

BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that positive preclinical results of BL-8040...


Nov 26, 2013, 07:00 ET BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment

 BioLineRx (NASDAQ: BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today additional Phase 2a results showing significant...


Nov 19, 2013, 07:00 ET BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today the publication of results showing that...


Nov 06, 2013, 07:00 ET BioLineRx to Report Third Quarter 2013 Results on November 13, 2013

 BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it will release its unaudited financial...


Nov 04, 2013, 07:00 ET BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease

 BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has received regulatory approval from...


Oct 23, 2013, 07:00 ET BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes

 BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has signed a worldwide, exclusive...


Sep 24, 2013, 06:00 ET BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease

BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has filed the necessary regulatory...


Sep 09, 2013, 07:00 ET BioLineRx's BL-8040 Receives Orphan Drug Designation for Treatment of AML

BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that the U.S. Food & Drug Administration (FDA)...


Sep 03, 2013, 08:00 ET BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York

 BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret...


Sep 03, 2013, 07:00 ET BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that an Issue Notification has been received...


Aug 28, 2013, 07:00 ET BioLineRx to Present at 15th International Celiac Disease Symposium

 BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its abstract entitled "BL-7010:...


Aug 27, 2013, 07:00 ET BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston

 BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret...


Aug 19, 2013, 07:00 ET BioLineRx Appoints B. J. Bormann to Board of Directors

 BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today the appointment of B. J. Bormann, Ph.D., to...


Aug 05, 2013, 07:00 ET BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical...